Integrated analysis identifies a pathway-related competing endogenous RNA network in the progression of pancreatic cance
- PDF / 3,185,572 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 198 Views
RESEARCH ARTICLE
Open Access
Integrated analysis identifies a pathwayrelated competing endogenous RNA network in the progression of pancreatic cancer Fuqiang Zu1, Peng Liu2, Huaitao Wang2, Ting Zhu1, Jian Sun3, Weiwei Sheng3 and Xiaodong Tan2*
Abstract Background: It is well acknowledged that cancer-related pathways play pivotal roles in the progression of pancreatic cancer (PC). Employing Integrated analysis, we aim to identify the pathway-related ceRNA network associated with PC progression. Methods: We divided eight GEO datasets into three groups according to their platform, and combined TCGA and GTEx databases as a group. Additionally, we screened out the differentially expressed genes (DEGs) and performed functional enrichment analysis in each group, and recognized the top hub genes in the most enriched pathway. Furthermore, the upstream of miRNAs and lncRNAs were predicted and validated according to their expression and prognostic roles. Finally, the co-expression analysis was applied to identify a pathway-related ceRNA network in the progression of PC. Results: A total of 51 significant pathways that common enriched in all groups were spotted. Enrichment analysis indicated that pathway in cancer was greatly linked with tumor formation and progression. Next, the top 20 hug genes in this pathway were recognized, and stepwise prediction and validation from mRNA to lncRNA, including 11 hub genes, 4 key miRNAs, and 2 key lncRNAs, were applied to identify a meaningful ceRNA network according to ceRNA rules. Ultimately, we identified the PVT1/miR-20b/CCND1 axis as a promising pathway-related ceRNA axis in the progression of PC. Conclusion: Overall, we elucidate the pathway-related ceRNA regulatory network of PVT1/miR-20b/CCND1 in the progression of PC, which can be considered as therapeutic targets and encouraging prognostic biomarkers for PC. Keywords: Integrated analysis, Cancer pathways, Competing endogenous RNA, Pancreatic cancer, Progression
Background Despite advances in treatments for pancreatic cancer (PC), the outcome of patients remains unsatisfying, with a five-year survival of < 5% [1]. What’s worse, owing to a lack of specific symptoms in the early stage, the majority * Correspondence: [email protected] 2 Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China Full list of author information is available at the end of the article
of patients with PC are in advanced stages, which lost the chances for a radical resection [2]. Therefore, it’s urgently necessary to figure out how PC occurs and progresses, and recognize novel therapeutic targets for PC. As is well known that cancer-related pathways play significant roles in the progression of PC, and genes with similar functions cluster together to form a regulatory pathway [3]. what’s more, non-coding RNAs (ncRNAs) are found to be abundant in the human genome, which
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which per
Data Loading...
